SN5
SHORT NOTE
5M
★ High-yield
Describe cisplatin and the platinum compounds with their uses and toxicity.
Mechanism and the Platinum Compounds
Cisplatin is a platinum coordination complex that forms intrastrand and interstrand DNA cross-links, chiefly between adjacent guanines. It behaves like an alkylating agent and is cell cycle non-specific.
| Drug | Distinctive features | Dose-limiting toxicity |
|---|---|---|
| Cisplatin | The most potent; requires vigorous hydration | Nephrotoxicity |
| Carboplatin | Much less nephrotoxic, ototoxic and emetogenic; dosed by renal function using the Calvert formula rather than by surface area | Myelosuppression, particularly thrombocytopenia |
| Oxaliplatin | Active in colorectal cancer, where the others are not; a component of FOLFOX | Peripheral neuropathy, characteristically triggered and worsened by cold |
Uses
- Testicular cancer — cisplatin-based combination therapy (BEP) transformed a usually fatal disease into one cured in the great majority, and remains among the outstanding achievements of medical oncology
- Ovarian cancer — carboplatin with paclitaxel
- Lung cancer, both small cell and non-small cell
- Head and neck cancer, often with radiotherapy as a radiosensitiser
- Bladder, cervical, oesophageal and gastric cancer
- Colorectal cancer — oxaliplatin specifically
Toxicity of Cisplatin
| Toxicity | Features | Prevention |
|---|---|---|
| Nephrotoxicity — dose-limiting | Proximal tubular damage, reduced glomerular filtration, and marked renal wasting of magnesium and potassium; may be cumulative and irreversible | Vigorous pre- and post-hydration with saline, forced diuresis, magnesium supplementation, and avoiding other nephrotoxins |
| Severe vomiting | Among the most emetogenic drugs known; both acute and delayed | 5-HT3 antagonist + dexamethasone + NK1 antagonist, given prophylactically |
| Ototoxicity | Irreversible high-frequency sensorineural hearing loss and tinnitus, from hair cell damage; particularly serious in children | Baseline and serial audiometry; sodium thiosulphate is protective in children |
| Peripheral neuropathy | Sensory, glove-and-stocking, cumulative; often incompletely reversible | Dose reduction; no effective prophylaxis |
| Electrolyte disturbance | Hypomagnesaemia (almost universal), hypokalaemia, hypocalcaemia | Routine magnesium replacement |
| Myelosuppression | Moderate | Monitoring |
| Others | Hypersensitivity; rarely optic neuritis and haemolytic-uraemic syndrome | — |
CLINICAL PEARL
Cisplatin is nephrotoxic and its major toxicities are all cumulative and largely irreversible — which changes how the drug is given. Hearing loss, neuropathy and renal damage do not recover meaningfully when the drug is stopped, so the emphasis falls entirely on prevention: hydration before the damage, audiometry before the deafness, and a decision to reduce or switch to carboplatin before the neuropathy is disabling.
Resistance
- Increased DNA repair of platinum adducts — the principal mechanism, which is why tumours with defective repair (BRCA-mutated) are unusually platinum-sensitive
- Inactivation by glutathione and metallothioneins, which bind the platinum
- Reduced uptake through loss of the copper transporter CTR1
- Failure of apoptosis, often through p53 mutation
- "Platinum-sensitive" relapse — in ovarian cancer, relapse more than 6 months after treatment usually responds to platinum again, whereas earlier relapse does not; this distinction guides second-line treatment
Applied Aspects
- Never give cisplatin without adequate hydration and a check of renal function and magnesium before each cycle
- Check magnesium routinely and replace it; hypomagnesaemia is almost universal, causes tetany, arrhythmia and weakness, and prevents correction of potassium and calcium until it is treated
- Arrange audiometry in children before and during treatment; hearing loss in a child has lifelong consequences for language and schooling, and switching to carboplatin may be preferable
- Substitute carboplatin where renal function, hearing or neuropathy are a concern, accepting greater myelosuppression in exchange
- Warn oxaliplatin patients to avoid cold drinks, cold air and touching cold objects in the days after infusion, since cold precipitates distressing pharyngolaryngeal dysaesthesia
- Discuss fertility and sperm banking before treatment, particularly in testicular cancer where the patients are young and the cure rate is high — they will live with the consequences for decades
All questions in Blood, Haematinics & Anticancer Drugs
- Q1Define haematinics. Describe iron metabolism, iron preparations, vitamin B12 and folic acid with their uses. ★
- Q2Classify the haemostatic drugs. Describe vitamin K, tranexamic acid and the treatment of haemophilia. ★
- Q3Describe the general principles of cancer chemotherapy including the cell cycle, log kill hypothesis, combination therapy, resistance and toxicity. ★
- Q4Classify the cytotoxic anticancer drugs. Describe the alkylating agents, antimetabolites and natural products with their distinctive toxicities. ★
- Q5Describe the hormonal agents, targeted therapy and immunotherapy used in cancer. ★
- SN1Describe oral and parenteral iron therapy with the monitoring of response and the management of iron overload. ★
- SN2Describe vitamin B12 and folic acid with their deficiency states and treatment. ★
- SN3Describe the haematopoietic growth factors with their uses and adverse effects. ★
- SN4Describe methotrexate with its mechanism, uses, adverse effects and interactions. ★
- SN5Describe cisplatin and the platinum compounds with their uses and toxicity. ★
- SN6Describe the adverse effects of cancer chemotherapy and their prevention and management. ★
- SN7Classify the immunosuppressant drugs. Describe the calcineurin inhibitors and the complications of immunosuppression.